Hetero To Supply 60,000 Vials Of Generic Remdesvir In India This Week
A nurse prepares an injection for a patient with Covid-19 on an ICU at Frimley Park Hospital, operated by Frimley Health NHS Foundation Trust, in Camberley, U.K.(Photographer: Steve Parsons/PA Wire/Bloomberg)

Hetero To Supply 60,000 Vials Of Generic Remdesvir In India This Week


Hetero Healthcare Ltd is supplying 60,000 vials of Covifor, generic version of Remdesivir injection in the country from July 13 to 20, the company website said.

Covifor is the first generic brand of Remdesivir, which is meant for the treatment of Covid-19 patients hospitalised with severe symptoms of the disease. The drug is available in 100 mg injectable vials.

It needs to be administered intravenously in a hospital, critical care setting, under the supervision of a registered medical practitioner. Out of the 60,000 vials, Maharashtra, which has the highest number of Covid-19 cases in the country will get 12,500, followed by Delhi and Telangana that will get 10,000 and 9,000 respectively.

According to the website, Tamil Nadu, Gujarat, Andhra Pradesh and Karnataka will get 7,500, 6,000, 2,000 and 3,000 respectively, while the rest of the country will get 10,000 injections.

The company has supplied the drug to as many as 166 hospitals in Maharashtra and 53 in the national capital. When it comes to Telangana, Hetero provided 14,502 vials, the information available at 11 a.m. on Wednesday.

Remdesivir is the only drug approved by the United States Food and Drug Administration for emergency use authorisation treatment of adult and paediatric patients hospitalised with suspected or laboratory-confirmed Covid-19 infection.

Meanwhile, Dr Reddy's Laboratories Ltd. which has a non-exclusive licensing agreement with Gilead Sciences to register, manufacture and sell Remdesivir in 127 countries including India, is yet to get a nod from the DCGI to start making the drug in the country, sources said.

BQ Install

Bloomberg Quint

Add BloombergQuint App to Home screen.